Mads Bodenhoff Sells 3,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Ascendis Pharma A/S Trading Up 0.2%

Shares of ASND stock opened at $261.23 on Friday. The company’s fifty day simple moving average is $257.64 and its two-hundred day simple moving average is $241.97. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. Ascendis Pharma A/S has a 1 year low of $186.05 and a 1 year high of $282.15. The stock has a market capitalization of $16.30 billion, a price-to-earnings ratio of 20.27 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, analysts anticipate that Ascendis Pharma A/S will post 5.15 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently modified their holdings of the business. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth approximately $26,000. Arax Advisory Partners lifted its position in Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares during the last quarter. Leonteq Securities AG bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at approximately $42,000. Finally, Global Retirement Partners LLC grew its stake in Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ASND shares. Morgan Stanley decreased their price target on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. Citigroup started coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Bank of America decreased their target price on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Evercore reiterated an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average price target of $310.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.